Back to Search
Start Over
Moderate-to-severe atopic dermatitis in adolescents treated with dupilumab: A multicentre Italian real-world experience
- Publication Year :
- 2022
-
Abstract
- Background Moderate-to-severe atopic dermatitis (AD) in the adolescence is a high burden disease, and its treatment can be very challenging due to paucity of approved systemic drugs for this age and their side-effects. Dupilumab was recently approved for treatment of adolescent AD. Objectives A multicentre, prospective, real-world study on the effectiveness and safety of dupilumab in adolescents (aged from >= 12 to
- Subjects :
- SARS-CoV-2
Pruritus
Eczema
COVID-19
Dermatitis
Dermatology
Antibodies, Monoclonal, Humanized
Severity of Illness Index
Atopic
Antibodies
COVID-19 Drug Treatment
Dermatitis, Atopic
Treatment Outcome
Settore MED/35
Infectious Diseases
Double-Blind Method
Monoclonal
Humans
Prospective Studies
Settore MED/35 - MALATTIE CUTANEE E VENEREE
Pandemics
Humanized
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....d3cf59659af4e7e1735ff9dcfde701ea